Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Ernexa Therapeutics (Nasdaq: ERNA) said it participated in a Virtual Investor "What This Means" segment after a successful Pre-IND meeting with the U.S. FDA.

Rhea-AI Summary

Ernexa Therapeutics (Nasdaq: ERNA) said it participated in a Virtual Investor "What This Means" segment after a successful Pre-IND meeting with the U.S. FDA. The company reported FDA regulatory alignment on development strategy for lead cell therapy ERNA-101, targeting a first-in-human ovarian cancer trial.

Ernexa indicated it plans to submit an IND and initiate clinical testing in H2 2026, and that clinical-grade manufacturing technology transfer is underway to accelerate operational readiness for its allogeneic iMSC programs.

Positive

• FDA provided regulatory alignment on ERNA-101 development strategy
• Company expects to submit an IND and start trials in H2 2026
• Clinical-grade manufacturing technology transfer is already underway

Negative

• None.

Argus Feb 3 session

-25.80% close to close Open Argus

Details

News Market Reaction – ERNA

On Feb 3, the day this news came out, ERNA closed 25.80% below the previous close.

Data tracked by StockTitan Argus for the Feb 3 session.

Key Figures

Planned IND timeline: Second half of 2026

Planned IND timeline

Second half of 2026

Target for IND submission and first-in-human trial start

Historical Context

5 past events · Latest: Jan 27

5 events

1. Jan 27

   Expansion program

   24h Move

   -0.8%

   Selection for JETRO Japan Entry Acceleration Program to aid Japan expansion.

2. Jan 06

   Regulatory meeting

   24h Move

   +5.0%

   Successful Pre-IND FDA meeting clarifying IND path and FIH timing.

3. Dec 08

   Preclinical data

   24h Move

   -1.5%

   ASH data showing ERNA-101 reprograms tumor microenvironment in models.

4. Dec 03

   Conference presentation

   24h Move

   -4.2%

   Announcement of oral presentation on iMSC platform at ASH 2025.

5. Dec 02

   Advisory appointment

   24h Move

   -4.0%

   Appointment of gynecologic oncologist to strengthen advisory board.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pre-ind, investigational new drug application, first-in-human, allogeneic, +1 more

5 terms

pre-ind regulatory

"discussing the Company’s recent successful Pre-IND meeting with the U.S."

"Pre-ind" is short for "pre-indication" and refers to the period before a formal announcement or official signal that a significant change or event is about to happen, such as a company preparing to release important news. For investors, it can signal a time of increased activity or uncertainty, as market participants try to interpret hints and anticipate future developments. Recognizing pre-ind conditions helps investors make more informed decisions ahead of major shifts.

investigational new drug application regulatory

"provides a clear pathway toward submitting an Investigational New Drug application"

An investigational new drug application is a formal request made to regulatory authorities to begin testing a new medication in humans. It is a critical step in the drug development process, as approval indicates the drug has passed initial safety checks and can be studied further. For investors, this signals that a potential new treatment is progressing through its early testing stages, which can impact the company's future growth prospects.

first-in-human medical

"continued advancement toward a first-in-human trial for ovarian cancer."

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

allogeneic medical

"advance its synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapies"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

induced mesenchymal stem cell medical

"synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapies designed"

An induced mesenchymal stem cell is a cell that has been converted in the lab from another cell type to behave like a natural mesenchymal stem cell, capable of becoming connective tissues (bone, cartilage, fat) and calming inflammation. Think of it as retraining a worker to perform a new, valuable job; for investors this matters because these lab-made cells are the basis for potential therapies, manufacturing and regulatory risk, intellectual property, and future revenue if safety and effectiveness are proven.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Access the “What This Means” segment here

CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a Virtual Investor "What This Means" segment discussing the Company’s recent successful Pre-IND meeting with the U.S. Food and Drug Administration and its continued advancement toward a first-in-human trial for ovarian cancer.

As part of the segment, Sanjeev Luther, President & CEO of Ernexa, highlighted how regulatory alignment from the FDA on Ernexa’s development strategy for its lead cell therapy, ERNA-101, provides a clear pathway toward submitting an Investigational New Drug application and initiating clinical testing in the second half of 2026. This reinforces that technology transfer for clinical-grade manufacturing is already underway, accelerating operational readiness and positioning Ernexa to advance its synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapies designed to target ovarian cancer and autoimmune disease.

The Virtual Investor “What This Means” segment featuring Ernexa can be accessed here.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.

For more information, visit www.ernexatx.com.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ernexa (ERNA) report about its Pre-IND meeting with the FDA on Feb 3, 2026?

Ernexa said the Pre-IND meeting gave regulatory alignment on its ERNA-101 development approach. According to the company, this alignment provides a clear pathway to submit an IND and pursue first-in-human trials targeting ovarian cancer.

When does Ernexa (ERNA) plan to submit an IND and begin clinical testing for ERNA-101?

Ernexa plans to submit an IND and initiate clinical testing in the second half of 2026. According to the company, the timeline follows FDA alignment and ongoing manufacturing technology transfer to support trial readiness.

How does Ernexa (ERNA) describe its manufacturing readiness for clinical trials?

Ernexa says clinical-grade manufacturing technology transfer is already underway to accelerate readiness. According to the company, this activity aims to enable scalable production for its allogeneic iMSC therapies ahead of IND submission.

What is ERNA-101 and which indications is Ernexa (ERNA) targeting with it?

ERNA-101 is Ernexa's lead synthetic, allogeneic iMSC cell therapy candidate targeting ovarian cancer and autoimmune disease. According to the company, ERNA-101 is advancing toward first-in-human testing for ovarian cancer following FDA alignment.

Where can investors view Ernexa's Virtual Investor 'What This Means' segment about the FDA meeting?

The Virtual Investor segment featuring Ernexa is available online via the company's presentation access link. According to the company, the segment reviews the successful Pre-IND meeting and next steps toward IND submission.